Pathophysiological aspects of transferrin-A potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases
暂无分享,去创建一个
[1] Yi Wang,et al. The blood–brain barrier: Structure, regulation and drug delivery , 2023, Signal transduction and targeted therapy.
[2] A. Yusuf,et al. Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems , 2023, Polymers.
[3] Xiyun Yan,et al. Transferrin receptor 1 targeted nanomedicine for brain tumor therapy. , 2023, Biomaterials science.
[4] I. Boldyrev,et al. Intranasal Delivery of Liposomes to Glioblastoma by Photostimulation of the Lymphatic System , 2022, Pharmaceutics.
[5] Alexander S. Timin,et al. Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches , 2022, Journal of Nanobiotechnology.
[6] S. Mousa,et al. Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities , 2022, Heliyon.
[7] Wanqing Chen,et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants , 2022, Chinese medical journal.
[8] M. Coelho,et al. Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma , 2022, Pharmaceutics.
[9] C. Riccardi,et al. Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases , 2021, Pharmaceutics.
[10] Ludan Zhao,et al. A pH-sensitive T7 peptide-decorated liposome system for HER2 inhibitor extracellular delivery: an application for the efficient suppression of HER2+ breast cancer. , 2021, Journal of materials chemistry. B.
[11] G. Husseini,et al. Transferrin-modified liposomes triggered with ultrasound to treat HeLa cells , 2021, Scientific Reports.
[12] Xiaolu Liu,et al. Baicalein inhibits RLS3-induced ferroptosis in melanocytes. , 2021, Biochemical and biophysical research communications.
[13] Y. Kuo,et al. Multiple-component dual-phase solid lipid nanoparticles with conjugated transferrin for formulating antioxidants and nerve growth factor against neuronal apoptosis , 2020 .
[14] Steven J. P. McInnes,et al. Active targeting towards and inside the brain based on nanoparticles: A Review. , 2019, Current pharmaceutical biotechnology.
[15] Shubiao Zhang,et al. Targeting Strategies for SuperParamagnetic Iron Oxide Nanoparticles in Cancer Therapy. , 2019, Acta biomaterialia.
[16] Qiongxiu Zhou,et al. Mitochondria as a therapeutic target for ischemic stroke. , 2019, Free radical biology & medicine.
[17] Chengwen Sun,et al. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[18] M. Memo,et al. DMT1 Expression and Iron Levels at the Crossroads Between Aging and Neurodegeneration , 2019, Front. Neurosci..
[19] A. Grumezescu,et al. Nanomaterials for Drug Delivery to the Central Nervous System , 2019, Nanomaterials.
[20] Qian Zhang,et al. Transferrin-functionalised microemulsion co-delivery of β-elemene and celastrol for enhanced anti-lung cancer treatment and reduced systemic toxicity , 2019, Drug Delivery and Translational Research.
[21] M. Weller,et al. Chemotherapy sensitization of glioblastoma by focused ultrasound‐mediated delivery of therapeutic liposomes , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[22] J. Tsai,et al. A Rational Approach for Creating Peptides Mimicking Antibody Binding , 2019, Scientific Reports.
[23] Sushant Lakkadwala,et al. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model. , 2019, Colloids and surfaces. B, Biointerfaces.
[24] Yang Yang,et al. Dual-Modified Novel Biomimetic Nanocarriers Improve Targeting and Therapeutic Efficacy in Glioma. , 2018, ACS applied materials & interfaces.
[25] Shu-ling Wang,et al. Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy , 2018, International journal of nanomedicine.
[26] J. Jankovic,et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial , 2018, JAMA neurology.
[27] V. Torchilin,et al. Transferrin‐targeted, resveratrol‐loaded liposomes for the treatment of glioblastoma , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[28] M. Andjelkovic,et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.
[29] G. Cairo,et al. The transferrin receptor: the cellular iron gate. , 2017, Metallomics : integrated biometal science.
[30] B. Stockwell,et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease , 2017, Cell.
[31] Feng Xu,et al. Recent advances of controlled drug delivery using microfluidic platforms☆ , 2017, Advanced drug delivery reviews.
[32] O. Nedić,et al. A microscale protocol for the isolation of transferrin directly from serum. , 2017, Clinica chimica acta; international journal of clinical chemistry.
[33] A. Atilgan,et al. Mechanisms by Which Salt Concentration Moderates the Dynamics of Human Serum Transferrin. , 2017, The journal of physical chemistry. B.
[34] Zhenzhong Zhang,et al. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform. , 2017, Acta biomaterialia.
[35] S. Rivella,et al. A Red Carpet for Iron Metabolism , 2017, Cell.
[36] Gang Chen,et al. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases , 2016, Journal of cellular and molecular medicine.
[37] D. B. Vieira,et al. Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier , 2016, International journal of nanomedicine.
[38] Zhixing Zheng,et al. T7 Peptide-Functionalized PEG-PLGA Micelles Loaded with Carmustine for Targeting Therapy of Glioma. , 2016, ACS applied materials & interfaces.
[39] K. Rhodes,et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.
[40] Jiancheng Wang,et al. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles. , 2016, International journal of pharmaceutics.
[41] Hyun-soo Cho,et al. Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[42] M. Penichet,et al. Transferrin receptor 1: a target for antibody-mediated cancer therapy. , 2016, Immunotherapy.
[43] Chen Jiang,et al. Dual Functional Peptide-Driven Nanoparticles for Highly Efficient Glioma-Targeting and Drug Codelivery. , 2016, Molecular pharmaceutics.
[44] L. Lannfelt,et al. Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody , 2016, Alzheimer's Research & Therapy.
[45] Min‐Geol Lee,et al. Oxidative stress and antioxidant strategies in dermatology , 2016, Redox report : communications in free radical research.
[46] V. Ceña,et al. Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis. , 2016, Nanomedicine.
[47] G. Antoni,et al. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease , 2016, Nature Communications.
[48] Ying-zheng Zhao,et al. Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes , 2016, Cancer Chemotherapy and Pharmacology.
[49] T. Moos,et al. Revisiting nanoparticle technology for blood-brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[50] P. Vandenabeele,et al. Regulated necrosis: disease relevance and therapeutic opportunities , 2016, Nature Reviews Drug Discovery.
[51] B. Spellberg,et al. Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections. , 2015, Current opinion in microbiology.
[52] Mark E. Davis,et al. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core , 2015, Proceedings of the National Academy of Sciences.
[53] T. Moos,et al. Divalent metal transporter 1 (DMT1) in the brain: implications for a role in iron transport at the blood-brain barrier, and neuronal and glial pathology , 2015, Front. Mol. Neurosci..
[54] Atsushi B. Tsuji,et al. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models , 2015, PloS one.
[55] T. Garg,et al. Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor , 2015, Journal of drug targeting.
[56] M. Ghosh,et al. Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors , 2015, BioMed research international.
[57] P. Arosio,et al. The importance of iron in pathophysiologic conditions , 2015, Front. Pharmacol..
[58] I. Ahmed,et al. Development of microspheres for biomedical applications: a review , 2014, Progress in Biomaterials.
[59] Eric P. Skaar,et al. Transferrin iron starvation therapy for lethal bacterial and fungal infections. , 2014, The Journal of infectious diseases.
[60] P. Freskgård,et al. A Human Blood-Brain Barrier Transcytosis Assay Reveals Antibody Transcytosis Influenced by pH-Dependent Receptor Binding , 2014, PloS one.
[61] T. Rouault,et al. The physiological functions of iron regulatory proteins in iron homeostasis - an update , 2014, Front. Pharmacol..
[62] J. Robert,et al. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.
[63] Qiang Zhang,et al. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. , 2014, Biomaterials.
[64] Nick C Fox,et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[65] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[66] P. Oliveira,et al. Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy , 2014, Medicinal research reviews.
[67] Seong-Cheol Park,et al. Encapsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery. , 2013, International journal of pharmaceutics.
[68] Chi-Hwa Wang,et al. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. , 2013, Biomaterials.
[69] Zhijun Jia,et al. Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma. , 2013, European journal of pharmacology.
[70] Q. Lan,et al. Transferrin-modified Doxorubicin-loaded biodegradable nanoparticles exhibit enhanced efficacy in treating brain glioma-bearing rats. , 2013, Cancer biotherapy & radiopharmaceuticals.
[71] G. Barratt. Targeted drug delivery. Editorial. , 2013, International journal of pharmaceutics.
[72] Chen Jiang,et al. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. , 2013, International journal of pharmaceutics.
[73] Q. Lan,et al. Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations. , 2013, ACS applied materials & interfaces.
[74] Yu-Lan Hu,et al. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. , 2013, Biomaterials.
[75] H. Ackermann,et al. Transferrin-Coated Gadolinium Nanoparticles as MRI Contrast Agent , 2013, Molecular Imaging and Biology.
[76] M. Pellegrini,et al. Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.
[77] Xuwei Chen,et al. Quantum dots conjugated with Fe3O4-filled carbon nanotubes for cancer-targeted imaging and magnetically guided drug delivery. , 2012, Langmuir : the ACS journal of surfaces and colloids.
[78] S. Rocha,et al. TfR1 interacts with the IKK complex and is involved in IKK–NF-κB signalling , 2012, The Biochemical journal.
[79] H. Ackermann,et al. Contrast Enhancement of the Brain by Folate-Conjugated Gadolinium–Diethylenetriaminepentaacetic Acid–Human Serum Albumin Nanoparticles by Magnetic Resonance Imaging , 2012, Molecular imaging.
[80] J. Benoit,et al. Transferrin Adsorption onto PLGA Nanoparticles Governs Their Interaction with Biological Systems from Blood Circulation to Brain Cancer Cells , 2012, Pharmaceutical Research.
[81] Yan Li,et al. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. , 2012, Biomaterials.
[82] M. Cogné,et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors , 2012, The Journal of experimental medicine.
[83] R. MacGillivray,et al. Structure-based mutagenesis reveals critical residues in the transferrin receptor participating in the mechanism of pH-induced release of iron from human serum transferrin. , 2012, Biochemistry.
[84] R. Ippoliti,et al. Distinct cellular responses induced by saporin and a transferrin–saporin conjugate in two different human glioblastoma cell lines , 2012, Journal of cellular physiology.
[85] K. Pantopoulos,et al. Regulation of iron transport and the role of transferrin. , 2012, Biochimica et biophysica acta.
[86] B. Nemesure,et al. Differential Expression of Transferrin Receptor (TfR) in a Spectrum of Normal to Malignant Breast Tissues: Implications for In Situ and Invasive Carcinoma , 2011, Applied immunohistochemistry & molecular morphology : AIMM.
[87] J. Barton,et al. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. , 2011, Journal of hepatology.
[88] Xin-guo Jiang,et al. Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin. , 2011, Bioconjugate chemistry.
[89] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[90] Paul C. Wang,et al. A nanocomplex system as targeted contrast agent delivery vehicle for magnetic resonance imaging dynamic contrast enhancement study. , 2010, Journal of nanoscience and nanotechnology.
[91] Vincent M Rotello,et al. The role of surface functionality on acute cytotoxicity, ROS generation and DNA damage by cationic gold nanoparticles. , 2010, Small.
[92] Chee Wee Gan,et al. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. , 2010, Biomaterials.
[93] M. Rajput,et al. Microspheres in cancer therapy. , 2010, Indian journal of cancer.
[94] N. Plesnila,et al. Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[95] R. Murthy,et al. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic®P85, an in vitro cell line and in vivo biodistribution studies on rat model , 2009, Journal of drug targeting.
[96] M. Guo,et al. Iron-binding and anti-Fenton properties of baicalein and baicalin. , 2009, Journal of inorganic biochemistry.
[97] J. Sheng,et al. Growth Inhibition against Intracranial C6 Glioma Cells by Stereotactic Delivery of BCNU by Controlled Release from poly(D,L-lactic acid) Nanoparticles , 2009, Technology in cancer research & treatment.
[98] T. Daniels,et al. Conjugation of an anti–transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells , 2007, Molecular Cancer Therapeutics.
[99] T. Ganz,et al. Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia , 2007, Haematologica.
[100] E. Shusta,et al. Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.
[101] B. Davidson,et al. Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.
[102] T. Karagiannis,et al. Receptor-mediated DNA-targeted photoimmunotherapy. , 2006, Cancer research.
[103] N. Žarković,et al. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. , 2006, Cancer letters.
[104] G. Koning,et al. Radioprotective effect of transferrin targeted citicoline liposomes , 2006, Journal of drug targeting.
[105] J. Kamps,et al. Liposome Opsonization , 2005, Journal of liposome research.
[106] P. Aisen,et al. Transferrin receptor 1. , 2004, The international journal of biochemistry & cell biology.
[107] S. Sahoo,et al. Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer , 2004, International journal of cancer.
[108] C. Lécureuil,et al. Transgenic mice as a model to study the regulation of human transferrin expression in Sertoli cells. , 2004, Human reproduction.
[109] M. Büchler,et al. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. , 2004, European journal of cancer.
[110] W. Pardridge,et al. Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer , 2004, Clinical Cancer Research.
[111] B. Jaber,et al. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[112] R. Graf,et al. Cerebral Ischemia and Reperfusion: The Pathophysiologic Concept as a Basis for Clinical Therapy , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[113] W. Buurman,et al. Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury1 , 2004, Transplantation.
[114] J. Wernly. Ischemia, reperfusion, and the role of surgery in the treatment of cardiogenic shock secondary to acute myocardial infarction: an interpretative review. , 2004, The Journal of surgical research.
[115] L. Lai,et al. Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. , 2003, Life sciences.
[116] C. Leisser,et al. Transferrin ensures survival of ovarian carcinoma cells when apoptosis is induced by TNFα, FasL, TRAIL, or Myc , 2003, Oncogene.
[117] Michael Weaver,et al. Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas , 2003, Journal of Neuro-Oncology.
[118] Lei Shi,et al. The inhibitory activity of serum to prevent bacterial adhesion is mainly due to apo-transferrin. , 2003, Journal of biomedical materials research. Part A.
[119] T. Ruutu,et al. Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. , 2003, FEMS immunology and medical microbiology.
[120] Corina I. García,et al. Differential effects of apotransferrin on two populations of oligodendroglial cells , 2003, Glia.
[121] M. Shoji,et al. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin , 2003, Neurological research.
[122] C. van Campenhout,et al. Transferrin Modifications and Lipid Peroxidation: Implications in Diabetes Mellitus , 2003, Free radical research.
[123] Hongzhe Sun,et al. Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway , 2002, Pharmacological Reviews.
[124] K. Kowdley,et al. Haemochromatosis , 2002, Alimentary pharmacology & therapeutics.
[125] K. Kamiński,et al. Oxidative stress and neutrophil activation--the two keystones of ischemia/reperfusion injury. , 2002, International journal of cardiology.
[126] J. Parkkinen,et al. Function and Therapeutic Development of Apotransferrin , 2002, Vox sanguinis.
[127] E. Wagner,et al. Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment , 2002, Gene Therapy.
[128] S. Kane,et al. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. , 2002, Cancer letters.
[129] Z. Qian,et al. Transferrin/transferrin receptor‐mediated drug delivery , 2002, Medicinal research reviews.
[130] K. Maruyama,et al. Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer , 2002, International journal of cancer.
[131] D. Richardson,et al. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? , 2002, Critical reviews in oncology/hematology.
[132] P. Sadler,et al. Unusual features for zirconium(IV) binding to human serum transferrin , 2002, JBIC Journal of Biological Inorganic Chemistry.
[133] T. Momoi,et al. Induction of bud formation of embryonic mouse tracheal epithelium by fibroblast growth factor plus transferrin in mesenchyme‐free culture , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.
[134] H. Deeg,et al. Pro-apoptotic and anti-apoptotic effects of transferrin and transferrin-derived glycans on hematopoietic cells and lymphocytes. , 2001, Experimental hematology.
[135] E. Beutler,et al. Molecular characterization of a case of atransferrinemia. , 2000, Blood.
[136] S. P. Vyas,et al. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery. , 2000, Advanced drug delivery reviews.
[137] R. MacGillivray,et al. The chloride effect is related to anion binding in determining the rate of iron release from the human transferrin N-lobe. , 2000, The Biochemical journal.
[138] N. Andrews,et al. The molecular defect in hypotransferrinemic mice. , 2000, Blood.
[139] Hiroshi Kawabata,et al. Transferrin Receptor 2-α Supports Cell Growth Both in Iron-chelated Cultured Cells and in Vivo * , 2000, The Journal of Biological Chemistry.
[140] R. Elliott,et al. Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. , 2000, Anticancer research.
[141] M. Hirose. The Structural Mechanism for Iron Uptake and Release by Transferrins , 2000, Bioscience, biotechnology, and biochemistry.
[142] P J Sadler,et al. Transferrin as a metal ion mediator. , 1999, Chemical reviews.
[143] H. Koeffler,et al. Molecular Cloning of Transferrin Receptor 2 , 1999, The Journal of Biological Chemistry.
[144] N. Ohkohchi,et al. Kupffer's cells modulate neutrophile activity by superoxide anion and tumor necrosis factor-delta in reperfusion injury of liver transplantation-mechanisms of radical generation and reperfusion injury after cold ischemia. , 1999, Transplantation proceedings.
[145] H. Baker,et al. Two high-resolution crystal structures of the recombinant N-lobe of human transferrin reveal a structural change implicated in iron release. , 1998, Biochemistry.
[146] E. Morgan,et al. Transport mechanisms for iron and other transition metals in rat and rabbit erythroid cells , 1998, The Journal of physiology.
[147] R. Micetich,et al. Transferrin directed delivery of adriamycin to human cells. , 1998, Anticancer research.
[148] D. Ribatti,et al. Transferrin Promotes Endothelial Cell Migration and Invasion: Implication in Cartilage Neovascularization , 1997, The Journal of cell biology.
[149] T. Okamoto,et al. Effects of insulin and transferrin on the generation of lymphokine-activated killer cells in serum-free medium. , 1996, Journal of immunological methods.
[150] K. Sakurai,et al. Inhibition of microsomal lipid peroxidation by baicalein: A possible formation of an iron‐baicalein complex , 1996, Biochemistry and molecular biology international.
[151] B. Lönnerdal,et al. Lactoferrin: molecular structure and biological function. , 1995, Annual review of nutrition.
[152] G. Nicolson,et al. The role of trophic factors and autocrine/paracrine growth factors in brain metastasis , 1995, Clinical & Experimental Metastasis.
[153] R. Cancedda,et al. Ovotransferrin and ovotransferrin receptor expression during chondrogenesis and endochondral bone formation in developing chick embryo , 1994, The Journal of cell biology.
[154] Y. Wada,et al. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. , 1993, American journal of human genetics.
[155] N. Brünner,et al. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials , 1993, Journal of cellular physiology.
[156] B. Lönnerdal,et al. Lactoferrin, lactoferrin receptors and iron metabolism. , 1993, European journal of clinical nutrition.
[157] R. Pakala,et al. Thyroid hormone dependent pituitary tumor cell growth in serum-free chemically defined culture. A new regulatory role for apotransferrin. , 1991, Biochemistry.
[158] R. Starzyk,et al. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[159] R. Weissleder,et al. Receptor imaging: application to MR imaging of liver cancer. , 1990, Radiology.
[160] M. Skinner,et al. Transferrin gene expression and synthesis by cultured choroid plexus epithelial cells. Regulation by serotonin and cyclic adenosine 3',5'-monophosphate. , 1989, The Journal of biological chemistry.
[161] M. Grisham,et al. A role for iron in oxidant-mediated ischemic injury to intestinal microvasculature. , 1987, The American journal of physiology.
[162] C. Finch,et al. The physiology of transferrin and transferrin receptors. , 1987, Physiological reviews.
[163] E. Ozawa,et al. Class specificity of transferrin as a muscle trophic factor , 1986, Journal of cellular physiology.
[164] W. Dreyer,et al. Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[165] B. Bloch,et al. Transferrin gene expression visualized in oligodendrocytes of the rat brain by using in situ hybridization and immunohistochemistry. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[166] F. Schoentgen,et al. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. , 1984, European journal of biochemistry.
[167] B. Iacopetta,et al. Intravesicular pH and iron uptake by immature erythroid cells , 1984, Journal of cellular physiology.
[168] C. Hopkins,et al. Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells , 1983, The Journal of cell biology.
[169] A. Ciechanover,et al. pH and the recycling of transferrin during receptor-mediated endocytosis. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[170] T. Elleman,et al. The primary structure of hen ovotransferrin. , 1982, European journal of biochemistry.
[171] I. Trowbridge,et al. Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells , 1981, Nature.
[172] P. Aisen,et al. Distribution of iron between the binding sites of transferrin in serum: methods and results in normal human subjects. , 1979, Blood.
[173] E. Morgan,et al. The kinetics of the interaction between rabbit transferrin and reticulocytes. , 1969, Biochemistry.
[174] H. S. Gutowsky,et al. NUCLEAR MAGNETIC RESONANCE , 1954 .
[175] A. L. Schade,et al. An Iron-binding Component in Human Blood Plasma. , 1946, Science.
[176] A. Stack,et al. Transferrin Saturation: A Body Iron Biomarker. , 2016, Advances in clinical chemistry.
[177] Jonathan D. Ashley,et al. Ligand-targeted liposome design: challenges and fundamental considerations. , 2014, Trends in biotechnology.
[178] Ying Zhang,et al. Advanced materials and processing for drug delivery: the past and the future. , 2013, Advanced drug delivery reviews.
[179] C. Baines,et al. Cell biology of ischemia/reperfusion injury. , 2012, International review of cell and molecular biology.
[180] N. Sibson,et al. Detection of brain pathology by magnetic resonance imaging of iron oxide micro-particles. , 2011, Methods in molecular biology.
[181] R. Choudhury,et al. Chapter 4 - Applications of nanotechnology in molecular imaging of the brain. , 2009, Progress in brain research.
[182] Sanjay K. Jain,et al. PEGylation: an approach for drug delivery. A review. , 2008, Critical reviews in therapeutic drug carrier systems.
[183] K. Zirvi. Development of serum-free media for the growth of human gastrointestinal adenocarcinoma xenografts as primary tissue cultures , 2005, Journal of Cancer Research and Clinical Oncology.
[184] Ernest Beutler,et al. Iron deficiency and overload. , 2003, Hematology. American Society of Hematology. Education Program.
[185] S. Vyas,et al. Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. , 2001, Critical reviews in therapeutic drug carrier systems.
[186] R. Elliott,et al. Antineoplastic drugs that interfere with iron metabolism in cancer cells. , 1997, Advances in enzyme regulation.
[187] L. Yeoman,et al. Transferrin and insulin enhance human colon tumor cell growth by differentiation class specific mechanisms. , 1996, Oncology research.
[188] S. E. Bernstein. Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. , 1987, The Journal of laboratory and clinical medicine.
[189] P. Cohen,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Transferrin Is an Insulin-Like Growth Factor-Binding Protein-3 Binding Protein* , 2022 .